In October, 2023 Lung Therapeutics was acquired by Aileron Therapeutics. Since then, Aileron has rebranded to Rein Therapeutics. Rein is now a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit https://reintx.com
Company Details
- Employees
- 10
- Founded
- -
- Address
- 3801 S Capitol Of Tx Hwy,
- Phone
- 737-802-1989
- in****@****gtx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- lungtx.com
- HQ
- Austin, TX
Lung Therapeutics Questions
Lung Therapeutics's helpline number is 737-802-1989
Lung Therapeutics's website is lungtx.com
Lung Therapeutics's LinkedIn profile is https://www.linkedin.com/company/lung-therapeutics-inc-
Lung Therapeutics has
10 employees.
View email and phone details for 10
employees at Lung Therapeutics.
Lung Therapeutics's industry is
Biotechnology Research
Lung Therapeutics's top competitors are
Avalyn Pharma,
Ultragenyx,
Theravance Biopharma Us, Llc,
Oak Hill Bio,
Genentech,
Karuna Therapeutics,
Apellis Pharmaceuticals,
Apogee Therapeutics,
Rein Therapeutics,
Respira Therapeutics, Inc..
Lung Therapeutics's support email address is info@lungtx.com
Lung Therapeutics's categories are Biotechnology Research
Lung Therapeutics's founding year is 2013
